Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Lung Cancer

  Free Subscription


2 Ann Thorac Surg
1 Arch Bronconeumol
1 Arch Pathol Lab Med
3 BMC Cancer
1 Br J Cancer
1 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
3 Cancer Lett
1 Cancer Res
2 Cancer Sci
3 Clin Cancer Res
5 Clin Lung Cancer
1 Eur J Cardiothorac Surg
1 Hum Pathol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 J Clin Invest
15 J Thorac Oncol
1 Oncogene
1 Oncol Rep
2 Oncologist
1 PLoS One
3 Thorax

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Ann Thorac Surg

  1. SHEWALE JB, Nelson DB, Rice DC, Sepesi B, et al
    Natural History of Ground Glass Lesions among Patients with Previous Lung Cancer.
    Ann Thorac Surg. 2018 Feb 9. pii: S0003-4975(18)30146.
    PubMed     Text format     Abstract available

  2. SUZUKI S, Sakurai H, Yotsukura M, Masai K, et al
    Clinical Features of Ground Glass Opacity Dominant Lung Cancer Over 3.0 cm in the Whole Tumor Size.
    Ann Thorac Surg. 2018 Feb 7. pii: S0003-4975(18)30131.
    PubMed     Text format     Abstract available

    Arch Bronconeumol

  3. TORRES-DURAN M, Fernandez-Villar A, Ruano-Ravina A
    Lung Cancer Unrelated to Smoking.
    Arch Bronconeumol. 2018 Feb 5. pii: S0300-2896(18)30006.
    PubMed     Text format    

    Arch Pathol Lab Med

  4. DEL C MONROIG-BOSQUE P, Driver B, Morales-Rosado JA, Deavers M, et al
    Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
    Arch Pathol Lab Med. 2018 Feb 12. doi: 10.5858/arpa.2017-0516.
    PubMed     Text format     Abstract available

    BMC Cancer

  5. BHANGOO MS, Zhou JY, Ali SM, Madison R, et al
    Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report.
    BMC Cancer. 2017;17:197.
    PubMed     Text format     Abstract available

  6. CHU GCW, Lazare K, Sullivan F
    Serum and blood based biomarkers for lung cancer screening: a systematic review.
    BMC Cancer. 2018;18:181.
    PubMed     Text format     Abstract available

  7. WANG L, Liu D, Lu J, Zhang S, et al
    The feasibility and advantage of uniportal video-assisted thoracoscopic surgery (VATS) in pulmonary lobectomy.
    BMC Cancer. 2017;17:75.
    PubMed     Text format     Abstract available

    Br J Cancer

  8. HAN B, Li K, Zhao Y, Li B, et al
    Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Br J Cancer. 2018 Feb 13. pii: bjc2017478. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available

    Cancer Chemother Pharmacol

  9. SIENA L, Cipollina C, Di Vincenzo S, Ferraro M, et al
    Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth.
    Cancer Chemother Pharmacol. 2018 Feb 12. pii: 10.1007/s00280-018-3538.
    PubMed     Text format     Abstract available

    Cancer Epidemiol Biomarkers Prev

  10. TORRE LA, Islami F, Siegel RL, Ward EM, et al
    Global Cancer in Women: Burden and Trends.
    Cancer Epidemiol Biomarkers Prev. 2017;26:444-457.
    PubMed     Text format     Abstract available

    Cancer Lett

  11. TANG ZH, Lu JJ
    Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies.
    Cancer Lett. 2018 Feb 6. pii: S0304-3835(18)30129.
    PubMed     Text format     Abstract available

  12. ZHANG Y, Lin Q, Xu T, Deng W, et al
    Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer.
    Cancer Lett. 2018 Feb 6. pii: S0304-3835(18)30128.
    PubMed     Text format     Abstract available

  13. SAIJO A, Goto H, Nakano M, Mitsuhashi A, et al
    Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells.
    Cancer Lett. 2018 Feb 12. pii: S0304-3835(18)30143.
    PubMed     Text format     Abstract available

    Cancer Res

  14. DE S, Lindner DJ, Coleman C, Wildey G, et al
    The FACT inhibitor CBL0137 synergizes with cisplatin in small cell lung cancer by increasing NOTCH1 expression and targeting tumor-initiating cells.
    Cancer Res. 2018 Feb 13. pii: 0008-5472.CAN-17-1920.
    PubMed     Text format     Abstract available

    Cancer Sci

  15. OHARA Y, Chew SH, Shibata T, Okazaki Y, et al
    Phlebotomy as a preventive measure for crocidolite-induced mesothelioma in male rats.
    Cancer Sci. 2018;109:330-339.
    PubMed     Text format     Abstract available

  16. LI P, Zhang L, Yu X, Tong R, et al
    Proliferation genes in lung development associated with the prognosis of lung adenocarcinoma but not squamous cell carcinoma.
    Cancer Sci. 2018;109:308-316.
    PubMed     Text format     Abstract available

    Clin Cancer Res

  17. TIAN Y, Wang Z, Liu X, Duan J, et al
    Prediction of chemotherapeutic efficacy in non-small cell lung cancer by serum metabolomic profiling.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2855.
    PubMed     Text format     Abstract available

  18. YU J, Wang S, Zhao W, Duan J, et al
    Mechanistic exploration of cancer stem cell marker voltage-dependent calcium channel alpha2delta1 subunit-mediated chemotherapy resistance in small cell lung cancer.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-1932.
    PubMed     Text format     Abstract available

  19. MACLEOD AK, Lin, Huang JT, McLaughlin LA, et al
    Identification of novel pathways of osimertinib disposition and potential implications for the outcome of lung cancer therapy.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3555.
    PubMed     Text format     Abstract available

    Clin Lung Cancer

  20. KHUNGER M, Jain P, Rakshit S, Pasupuleti V, et al
    Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2018 Jan 10. pii: S1525-7304(18)30002.
    PubMed     Text format     Abstract available

  21. LANGER CJ, Paz-Ares LG, Wozniak AJ, Gridelli C, et al
    Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies.
    Clin Lung Cancer. 2017;18:489-496.
    PubMed     Text format     Abstract available

  22. REMON J, Menis J, Hasan B, Peric A, et al
    The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
    Clin Lung Cancer. 2017;18:583-588.
    PubMed     Text format     Abstract available

  23. TOYOKAWA G, Takada K, Okamoto T, Kozuma Y, et al
    High Frequency of Programmed Death-ligand 1 Expression in Emphysematous Bullae-associated Lung Adenocarcinomas.
    Clin Lung Cancer. 2017;18:504-511.
    PubMed     Text format     Abstract available

  24. GIRARD P, Caliandro R, Seguin-Givelet A, Lenoir S, et al
    Sensitivity of Cytology Specimens From Bronchial Aspirate or Washing During Bronchoscopy in the Diagnosis of Lung Malignancies: An Update.
    Clin Lung Cancer. 2017;18:512-518.
    PubMed     Text format     Abstract available

    Eur J Cardiothorac Surg

  25. DECALUWE H, Moons J, Fieuws S, De Wever W, et al
    Is central lung tumour location really predictive for occult mediastinal nodal disease in (suspected) non-small-cell lung cancer staged cN0 on 18F-fluorodeoxyglucose positron emission tomography-computed tomography?
    Eur J Cardiothorac Surg. 2018 Feb 13. pii: 4855994. doi: 10.1093.
    PubMed     Text format     Abstract available

    Hum Pathol

  26. BOSCH DE, Farjah F, Wood DE, Schmidt RA, et al
    Regional lymph node sampling in lung carcinoma: a single institutional and national database comparison.
    Hum Pathol. 2018 Feb 12. pii: S0046-8177(18)30042.
    PubMed     Text format     Abstract available

    Int J Cancer

  27. LI X, Wang Y, Wang J, Zhang T, et al
    Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non-small cell lung cancer.
    Int J Cancer. 2018 Feb 12. doi: 10.1002/ijc.31303.
    PubMed     Text format     Abstract available

    Int J Radiat Oncol Biol Phys

  28. LEE J, Li B, Cui Y, Sun X, et al
    A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2018 Jan 10. pii: S0360-3016(18)30006.
    PubMed     Text format     Abstract available

    J Clin Invest

  29. TOUAT M, Sourisseau T, Dorvault N, Chabanon RM, et al
    DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade.
    J Clin Invest. 2018 Feb 15. pii: 90277. doi: 10.1172/JCI90277.
    PubMed     Text format     Abstract available

    J Thorac Oncol

  30. HEIGENER DF, Reck M
    PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?
    J Thorac Oncol. 2017;12:171-172.
    PubMed     Text format    

    Prognostic Value of Primary Tumor Volume Changes on Kilovoltage Onboard Cone Beam Computed Tomography during Definitive Chemoradiotherapy for stage III Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2018;13:e26-e27.
    PubMed     Text format    

  32. VAN DE GOOR R, van Hooren M, Dingemans AM, Kremer B, et al
    Training and validating a portable electronic nose for lung cancer screening.
    J Thorac Oncol. 2018 Feb 6. pii: S1556-0864(18)30093.
    PubMed     Text format     Abstract available

    Morphologic and Other Forms of Heterogeneity in Small Cell Lung Cancer: What Can We Learn from Them?
    J Thorac Oncol. 2018;13:148-150.
    PubMed     Text format    

  34. REULING EMBP, Dickhoff C, Daniels JMA
    Treatment of Bronchial Carcinoid Tumors: Is Surgery Really Necessary?
    J Thorac Oncol. 2017;12:e57-e58.
    PubMed     Text format    

  35. WARTH A, Beasley MB, Mino-Kenudson M
    Breaking New Ground: The Evolving Concept of Spread through Air Spaces (STAS).
    J Thorac Oncol. 2017;12:176-178.
    PubMed     Text format    

  36. MAO R, Chen C, Fei K
    The Clinical Implications and Thoughts on Different Patterns in Resected Lung Adenocarcinoma.
    J Thorac Oncol. 2017;12:e24-e25.
    PubMed     Text format    

  37. LEONE A
    C797S and T790M EGFR Mutations in Non-Small Cell Lung Cancer: In Trans or in Separate Clones?
    J Thorac Oncol. 2018;13:e21-e22.
    PubMed     Text format    

  38. LANTUEJOUL S, Le Stang N, Damiola F, Scherpereel A, et al
    PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?
    J Thorac Oncol. 2017;12:778-781.
    PubMed     Text format    

  39. SAVIC S, Rothschild S, Bubendorf L
    Lonely Driver ROS1.
    J Thorac Oncol. 2017;12:776-777.
    PubMed     Text format    

  40. BOTLING J, Sandelin M
    Immune Biomarkers on the Radar-Comprehensive "Immunograms" for Multimodal Treatment Prediction.
    J Thorac Oncol. 2017;12:770-772.
    PubMed     Text format    

  41. PETERS MLB, Costa DB, Rangachari D
    Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.
    J Thorac Oncol. 2017;12:e35-e36.
    PubMed     Text format    

  42. LAINE A, Choy H
    Single-Fraction Carbon Ion Radiotherapy for Early-Stage NSCLC-The Future Is Now.
    J Thorac Oncol. 2017;12:610-611.
    PubMed     Text format    

  43. JOHN T, Russell PA, Thapa B
    Is Mesothelioma in China Rare or Misdiagnosed?
    J Thorac Oncol. 2017;12:607-609.
    PubMed     Text format    

    The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma: Author's Reply.
    J Thorac Oncol. 2017;12:e25-e26.
    PubMed     Text format    


  45. LAI Q, Wang H, Li A, Xu Y, et al
    Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
    Oncogene. 2018 Feb 9. pii: 10.1038/s41388-018-0125.
    PubMed     Text format     Abstract available

    Oncol Rep

  46. KEERATICHAMROEN S, Lirdprapamongkol K, Svasti J
    Mechanism of ECM-induced dormancy and chemoresistance in A549 human lung carcinoma cells.
    Oncol Rep. 2018 Feb 12. doi: 10.3892/or.2018.6258.
    PubMed     Text format     Abstract available


  47. NISHIJIMA TF, Shachar SS, Nyrop KA, Muss HB, et al
    Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Oncologist. 2017;22:470-479.
    PubMed     Text format     Abstract available

  48. VON PAWEL J, Spigel DR, Ervin T, Losonczy G, et al
    Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
    Oncologist. 2018 Feb 7. pii: theoncologist.2017-0690.
    PubMed     Text format     Abstract available

    PLoS One

  49. KIRIU T, Yamamoto M, Nagano T, Hazama D, et al
    The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.
    PLoS One. 2018;13:e0193018.
    PubMed     Text format     Abstract available


  50. CROSBIE PA, Balata H, Evison M, Atack M, et al
    Implementing lung cancer screening: baseline results from a community-based 'Lung Health Check' pilot in deprived areas of Manchester.
    Thorax. 2018 Feb 13. pii: thoraxjnl-2017-211377.
    PubMed     Text format     Abstract available

  51. TEN HAAF K, van der Aalst CM, de Koning HJ
    Clinically detected non-aggressive lung cancers: implications for overdiagnosis and overtreatment in lung cancer screening.
    Thorax. 2018 Feb 9. pii: thoraxjnl-2017-211149.
    PubMed     Text format    

  52. SAITOH Y, Ohnishi-Amemiya A, Asano M, Tanaka Y, et al
    Unique radiological features of two cases of primary pulmonary diffuse large B-cell lymphoma.
    Thorax. 2017;72:859-860.
    PubMed     Text format    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.